for layman like me just a translation
The Phase II HERIZON trial evaluated HER-Vaxx, a B-cell peptide-based vaccine, in HER2-overexpressing advanced gastric cancer patients. The study showed a 40% overall survival (OS) benefit for patients receiving HER-Vaxx plus chemotherapy compared to chemotherapy alone. No additional toxicity from HER-Vaxx was observed. The vaccine induced strong HER2-specific antibody responses, which correlated with tumor reduction and improved OS. The results suggest HER-Vaxx could be a potential alternative to trastuzumab, especially when the latter is unavailable or not toleratedComparison of HER-Vaxx with Standard Care and Competing Products
Standard Care (Chemotherapy + Trastuzumab):
- Trastuzumab is the current standard for HER2-overexpressing advanced gastric cancer, combined with chemotherapy.
- Effectiveness: It has shown improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone.
- Limitations: Possible toxicity and availability issues.
HER-Vaxx (HERIZON Trial):
- Combination: HER-Vaxx + chemotherapy.
- Results: 40% OS benefit, 20% PFS benefit, no additional toxicity. High HER2-specific antibody response, leading to tumor reduction.
- Potential: May substitute trastuzumab in cases of unavailability or toxicity.
Competing Products in Clinical Trials:
- Other HER2-targeted Therapies:
- Zanidatamab (ZW25): Dual HER2-targeted bispecific antibody; in clinical trials showing promising efficacy in HER2-positive cancers.
- Margetuximab: HER2-targeted monoclonal antibody; enhances antibody-dependent cellular cytotoxicity (ADCC) more effectively than trastuzumab.
- DS-8201 (Trastuzumab Deruxtecan): Antibody-drug conjugate showing significant efficacy in HER2-positive tumors.
- Forums
- ASX - By Stock
- Media Thread
for layman like me just a translationThe Phase II HERIZON trial...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.2¢ |
Change
0.003(5.08%) |
Mkt cap ! $455.6M |
Open | High | Low | Value | Volume |
5.8¢ | 6.5¢ | 5.7¢ | $1.751M | 28.44M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 660964 | 6.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.2¢ | 549788 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 660964 | 0.061 |
10 | 1109613 | 0.060 |
3 | 465000 | 0.059 |
8 | 2031160 | 0.058 |
9 | 1210001 | 0.057 |
Price($) | Vol. | No. |
---|---|---|
0.062 | 549788 | 5 |
0.063 | 313635 | 6 |
0.064 | 1129381 | 10 |
0.065 | 1261036 | 13 |
0.066 | 1433220 | 8 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online